Canterbury DHB

Context

BEAM Conditioning

Calculation of Drug Dosages

In the seven schedules, drug dosage is related either to the patient’s actual body weight or by calculating the Body Surface area (BSA). Any dose reduction due to renal dysfunction or obesity is done by the Haematology Pharmacist in conjunction with the Transplant Consultant. See also Cytotoxic Drugs in the Drug Usage section.

The dose of melphalan should be no greater than 3.6 mg/kg (see Costa et al, BJH (2008) 143, 268-273).

Day

Time

Medication

-6

1000

Carmustine 300 mg/m2

-5

0830

Cytarabine 200 mg/m2 Q12H

 

0900

Etoposide 200 mg/m2

 

2030

Cytarabine 200 mg/m2 Q12H

-4

0830

Cytarabine 200 mg/m2 Q12H

 

0900

Etoposide 200 mg/m2

 

2030

Cytarabine 200 mg/m2 Q12H

-3

0830

Cytarabine 200 mg/m2 Q12H

 

0900

Etoposide 200 mg/m2

 

2030

Cytarabine 200 mg/m2 Q12H

-2

0830

Cytarabine 200 mg/m2 Q12H

 

0900

Etoposide 200 mg/m2

 

2030

Cytarabine 200 mg/m2 Q12H

-1

1000

Melphalan 140 mg/m2

0

24 hours following melphalan

For more details, refer to:

  • Administration details for BEAM.
  • Patient-specific schedule for BEAM.
  • Chemo chart for BEAM.
  • IV fluid chart for Melphalan.

About this Canterbury DHB document (284004):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

December 2016

Next Review:

December 2018

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 284004